Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Alpha Cognition Inc (ACOG)

Alpha Cognition Inc (ACOG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board Business Wire - Tue Jun 23, 7:30AM CDT

Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today...

ACOG : 8.52 (+0.24%)
ONCT : 0.5266 (-24.11%)
CBAY : 32.48 (+0.03%)
MIST : 1.3100 (+7.38%)
Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer’s Disease Business Wire - Tue Jun 16, 7:30AM CDT

Alpha Cognition, Inc. (ACOG: NASDAQ) (“Alpha Cognition” or the “Company”), a biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, today announced...

ACOG : 8.52 (+0.24%)
Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer’s Disease Business Wire - Tue Jun 9, 7:00AM CDT

In a retrospective observational study based on provider assessments and chart review: Providers reported cognitive improvement in 92% of patients following initiation...

ACOG : 8.52 (+0.24%)
MarketBeat.com
Alpha Cognition Q1 Earnings Call Highlights MarketBeat - Thu May 14, 5:10PM CDT

Alpha Cognition (NASDAQ:ACOG) reported 40% sequential revenue growth in the first quarter of 2026, as executives said commercial adoption of its Alzheimer’s treatment ZUNVEYL continued to build across...

ACOG : 8.52 (+0.24%)
Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update Business Wire - Thu May 14, 3:15PM CDT

ZUNVEYL generated net product revenue of $3.5 million in Q1 2026, a 40% quarter-over-quarter increase Cumulative net product revenue totaled $10.3 million through first...

ACOG : 8.52 (+0.24%)
Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026 Business Wire - Tue Apr 28, 3:30PM CDT

Management to host conference call on Thursday, May 14, 2026 at 4:30pm ET

ACOG : 8.52 (+0.24%)
Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences Business Wire - Mon Apr 27, 7:00AM CDT

Alpha Cognition, Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders,...

ACOG : 8.52 (+0.24%)
Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig Business Wire - Mon Apr 20, 4:00PM CDT

Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today...

KALV : 27.00 (+0.04%)
ACOG : 8.52 (+0.24%)
SUPN : 48.75 (-3.35%)
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Wed Apr 15, 7:00PM CDT

Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders,...

ACOG : 8.52 (+0.24%)
Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury Business Wire - Wed Apr 1, 3:30PM CDT

Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders,...

ACOG : 8.52 (+0.24%)

Barchart Exclusives

This Blue-Chip Dividend Stock Is Outperforming the S&P 500 in 2026 Barchart - Thu Jul 9, 6:30PM CDT
Merck & Co. has outperformed the S&P 500 in 2026, rising 19% year-to-date while offering a 2.61% dividend yield supported by 15 consecutive years of dividend increases. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.